EVAXION_DEEPBLUE_RGB.png
Evaxion announces business update and third quarter 2024 financial results
31 oct. 2024 08h00 HE | Evaxion Biotech
COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business...
EVAXION_DEEPBLUE_RGB.png
Evaxion to announce business update and third quarter 2024 financial results on October 31
28 oct. 2024 08h00 HE | Evaxion Biotech
COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a...
EVAXION_DEEPBLUE_RGB.png
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
09 oct. 2024 08h00 HE | Evaxion Biotech
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked...
EVAXION_DEEPBLUE_RGB.png
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
03 oct. 2024 08h00 HE | Evaxion Biotech
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through...
image1 (1).png
Evaxion significantly expands vaccine development collaboration with MSD
26 sept. 2024 07h30 HE | Evaxion Biotech
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on...
image1 (1).png
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
19 sept. 2024 08h00 HE | Evaxion Biotech
The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded dataset and includes an advanced protein prediction featureThe launch will expectedly...
image1 (1).png
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
16 sept. 2024 07h00 HE | Evaxion Biotech
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01’s vaccine targets...
image1 (1).png
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
09 sept. 2024 08h00 HE | Evaxion Biotech
Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16...
image1 (1).png
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
09 sept. 2024 07h00 HE | Evaxion Biotech
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...
image1 (1).png
Evaxion Announces Business Update and Second Quarter 2024 Financial Results
14 août 2024 07h00 HE | Evaxion Biotech
COPENHAGEN, Denmark, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines,...